Several large placebo-controlled trials in patients with T2D and cardiovascular disease have shown that GLP‐1R agonists, such as semaglutide, have a neutral effect on reducing risk for heart failure hospitalization [183–186]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.